Chronic heart failure (CHF) is a life-threatening disorder affecting millions worldwide, characterized by recurring symptoms such as shortness of breath, fluid retention, and fatigue, which significantly compromise daily functioning and contribute to elevated mortality and hospital readmissions. Qishen Yiqi Dropping Pills (QYDP), a formulation in Traditional Chinese Medicine (TCM) containing Danshen, Huangqi, Jiangxiang, and Sanqi, has shown promise in improving cardiac function by enhancing circulation and supporting Qi. Despite evidence from clinical studies suggesting symptom relief in CHF patients, the molecular mechanisms behind QYDP’s effects remain largely undefined. This study applied network pharmacology alongside molecular docking analyses to uncover potential therapeutic targets of QYDP in CHF. Four pivotal genes—AKT1, HIF1A, STAT3, and MYC—were identified, and their interactions with bioactive compounds in QYDP, including kaempferol, luteolin, quercetin, tanshinone IIa, and cryptotanshinone, were confirmed. The findings indicate that QYDP may act through multiple molecular pathways to exert cardioprotective effects, providing a foundation for deeper mechanistic research and potential clinical application.
